Get started

Swingtrading

Technical Analysis: Symmetrical Triangle Breakout in SBICARD • The weekly chart of SBI Cards (SBICARD) shows a symmetrical triangle pattern that has been forming since mid-2021. • The stock recently broke out of this pattern, indicating a potential trend reversal or continuation move depending on broader market conditions. • Resistance Breakout: The upper trendline, which acted as resistance, has been breached, and the stock is now retesting the breakout level (~800). • Volume Confirmation Needed: To validate the breakout, an increase in volume would be ideal. Fundamental Analysis: Mixed Earnings Performance • Earnings Per Share (EPS) Trends: • Q3 FY24 EPS came in at 4.25, missing estimates by 31.16%—a significant negative surprise. • Q2 FY24 EPS also missed estimates by 4.51%, while Q1 FY24 had a 4.59% miss as well. • The company has shown inconsistent earnings, which could cause volatility despite the technical breakout. • Revenue Growth: • Q3 FY24 revenue was ₹46.19B, exceeding estimates by 10.06%. • Q2 FY24 revenue missed expectations by 3.01%, while Q1 FY24 was also slightly weak. • This suggests that while top-line growth is strong, profitability (EPS) is under pressure due to either higher costs or operational inefficiencies. Investment View: Cautious Buy with Risk Management • Technical View: The breakout above the triangle is bullish, but the stock must sustain above 800-820 for confirmation. If it does, next resistance levels are 900 and 1000. • Fundamental Concerns: Weak earnings growth is a risk factor. The next earnings (April 2025) will be crucial. • Buying Strategy: • Entry: If the stock holds above 800-820, it can be bought with a target of 900-1000. • Stop Loss: 750-770 zone (below the breakout trendline). • Risk Factor: If broader market sentiment weakens or earnings disappoint further, the breakout might fail. Conclusion: A breakout trade is valid, but weak earnings make it a cautious buy with a tight stop loss. If fundamentals improve, the rally could sustain.
NSE:SBICARDLong
by Trade_lyst
Axis Bank : Swing Trade Pick#axisbank #swingtrade #momentumtrade #trendingstock Axis Bank : Swing Trade >> Low PE Stock >> Banking Sector Theme, most likely to perform >> Trending stock >> Low Risk Trade Swing Traders can lock profit at 10% and keep Trailing Please Boost, comment and follow us for more Learnings. Note : Markets are still Tricky and can go either ways so don't be over aggressive while choosing & planning your Trades, Calculate your Position sizing as per the Risk Reward you se and most importantly don't go all in Disc : Charts shared are for learning purpose only, not a Trade recommendation. Do your own research and consult your financial advisor before taking any position.
NSE:AXISBANKLong
by moneyfesttrading
Tata Motors-2-Chart AnalysisTata motors CMP:786.45; RSI: 36.35; TATAMOTORS has completed 5 wave impulsive -Primary Bull cycle phase on weekly chart basis and now in corrective of ABC wave in formation . Corrective Wave-A has bottomed out and wave-B may give a swing trade opportunity for aggressive trader . This wave-B may take the Tata Motors shares at levels of 969-980 levels. In Long term view is still avoid and fresh entry is suggested only for swing trade. On daily chart basis, also 5 wave structure has formed as identified in chart structure, It suggest script will now reverse as it has entered wave-a formation. Chart structure suggest a swing trade is open. The key crucial levels are listed below Swing Trade Target 1: 969-980; Target 2: 1000-1020. Stop Loss : 710 ✅ For more trading ideas like this, please like, share, and follow my Idea Stream ✅
NSE:TATAMOTORSLong
by DrPrashantVerma
#SHIVALIK - Potential Break Out / Feb'25📊 Script: SHIVALIK Key highlights: 💡⚡ 📈 IH&N Formation in Weekly chart. 📈 IH&N Formation in Daily chart also 📈 Price gave a good up move. 📈 Went into a Side Ways consolidation for over a Two months. 📈 Volume spike seen in past 📈 MACD Cross Over. 📈 One can go for Swing Trade. 🟢 If you have any questions regarding the setup, please feel free to leave your inquiries in the comments, and I will respond promptly. BUY ONLY ABOVE 850 DCB ⏱️ C.M.P 📑💰- 783 🟢 Target 🎯🏆 – NA% ⚠️ Stoploss ☠️🚫 – NA% ⚠️ Important: Always Exit the trade before any Event. ⚠️ Important: Always maintain your Risk & Reward Ratio. ✅#Boost, #Like & #Follow to never miss a new idea! ✅ Disclaimer: I am not SEBI Registered Advisor. My posts are purely for training and educational purposes. Eat🍜 Sleep😴 TradingView📈 Repeat 🔁 Happy learning with MMT. Cheers!🥂
NSE:SHIVALIKLong
by MMT_MakeMoneyTrading
#CANTABIL - Breakout Soon Candidate! /Feb'25/ 📊 Script: CANTABIL Key highlights: 💡⚡ 📈 C.E.S.T – refer image 🟢 If you have any questions regarding the setup, please feel free to leave your inquiries in the comments, and I will respond promptly. BUY ONLY ABOVE 315 DCB ⏱️ C.M.P 📑💰- 284 🟢 Target 🎯🏆 – NA% ⚠️ Stoploss ☠️🚫 – NA% ⚠️ Important: Always Exit the trade before any Event. ⚠️ Important: Always maintain your Risk & Reward Ratio. ✅#Boost, #Like & #Follow to never miss a new idea! ✅ Disclaimer: I am not SEBI Registered Advisor. My posts are purely for training and educational purposes. Eat🍜 Sleep😴 TradingView📈 Repeat 🔁 Happy learning with MMT. Cheers!🥂
NSE:CANTABILLong
by MMT_MakeMoneyTrading
CreditAccess Grameen: A Turnaround in Sight Short Term Trading Advice by Goodluck Capital Buy CreditAccess Grameen Buy Range- 990 - 1030 Target- 1200 - 1250 StopLoss- below 845 Upside Potential- 20% -25% Approx trade duration 20 - 25 days ◉ Technical Analysis ● After a substantial decline, the stock is now showing signs of recovery, bouncing back from its trendline support. ● Additionally, the increasing trading volume is reinforcing the likelihood of a turnaround, indicating a potential reversal in the stock's fortunes. ◉ Fundamental Rationale The Reserve Bank of India's (RBI) recent liquidity infusion of over ₹1.5 lakh crore is expected to boost economic growth and create a favorable environment for microfinance institutions (MFIs) like CreditAccess Grameen. Here are the key benefits: ● Improved Liquidity for Lending: The injection will help MFIs meet their short-term funding requirements, reducing their reliance on expensive sources of funding. ● Potential Interest Rate Cuts: Lower interest rates will enable CreditAccess Grameen to access cheaper capital, making loans more affordable for low-income customers. ● Boost to Rural Economy: Budget 2025's focus on rural development through increased government spending will enhance the repayment capacity of borrowers, reducing credit risks for MFIs. This will create a favorable environment for CreditAccess Grameen to operate and expand their services.
NSE:CREDITACCLong
by GoodluckCapital
TECH MAHINDRA - Good formations | Bullish OutlookPrice Analysis & Overview: 1. Prices are in uptrend. Forming HH-HL. 2. 1500 can be an immediate hurdle. 3. RRR is okay, but there might be chances for a better entry price than CMP on a pullback. 4. Good volume strength. 5. Expecting ATH breakout. Trade Plan: 1. ENTRY = CMP (1430) 2. SL = 10 % (1300) 3. TARGET = 1:2,1:3,1:4 - Stay tuned for further insights, updates and trade safely! - These are my personal views. - If you liked the analysis, don't forget to leave a comment and boost the post. Happy trading! Disclaimer: This is NOT a buy/sell recommendation. This post is meant for learning purposes only. Please, do your due diligence before investing. Thanks & Regards, Anubrata Ray
NSE:TECHMLong
by SuperNova396
1
ALIVUS - Breakout in Daily timeframeALIVUS (Alivus Life Sciences Limited, formerly Glenmark Life Sciences) - Breakout Breakout observed in daily timeframe of Alivus, the company has a very good chart pattern and is in a good uptrend and recently broke out with good volumes. The breakout has also been retested and sustained. There could be a good upside in this stock. The company also has good fundamentals as written below. Fundamentals. MCap 14,299Cr Stock P/E 32.4 Industry P/E 31.6 ROCE 28.1% ROE 21.1% NPM 20.6% PEG Ratio 1.69 Debt 16Cr Reserves 2,514Cr EPS 36.05 Promoter holding 75% API contribution 9MFY24 Chronic : 69% Acute : 31% Key Therapeutic areas contribution 9MFY24 Diabetes : 4% CVS : 41% CNS : 17% Pain Management : 6% Others : 32% Business segments The company has two key segments - Generics and Complex APIs (92% of FY23 revenue) and Contract Development and Manufacturing Operations (CDMO) (8% of FY23 revenue)
BSE:ALIVUSLong
by SwingtradesbyAbhishek